💥 Gate Square Event: #PostToWinCGN 💥
Post original content on Gate Square related to CGN, Launchpool, or CandyDrop, and get a chance to share 1,333 CGN rewards!
📅 Event Period: Oct 24, 2025, 10:00 – Nov 4, 2025, 16:00 UTC
📌 Related Campaigns:
Launchpool 👉 https://www.gate.com/announcements/article/47771
CandyDrop 👉 https://www.gate.com/announcements/article/47763
📌 How to Participate:
1️⃣ Post original content related to CGN or one of the above campaigns (Launchpool / CandyDrop).
2️⃣ Content must be at least 80 words.
3️⃣ Add the hashtag #PostToWinCGN
4️⃣ Include a screenshot s
AstraZeneca claims that an oral lipid-lowering drug can drop bad cholesterol by more than 50%.
Jin10 data reported on April 2, that AstraZeneca (AZN.O) presented clinical data on a new lipid-lowering drug under investigation at the American College of Cardiology Annual Scientific Session held in Chicago. The interim trial data shows that a PCSK9 (proprotein convertase subtilisin/kexin type 9) oral lipid-lowering drug being developed by the company can reduce “bad cholesterol” by nearly 51%. AstraZeneca stated that patients taking this oral lipid-lowering drug once daily in addition to standard statin therapy can lower their low-density lipoprotein (LDL) cholesterol levels by nearly 51% after 12 weeks. LDL, also known as “bad cholesterol,” is a major driver of cardiovascular events such as heart attacks and strokes.